New options for second-line therapy of advanced renal cancer
- PMID: 23598169
- DOI: 10.1016/S1470-2045(13)70119-0
New options for second-line therapy of advanced renal cancer
Comment on
-
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.Lancet Oncol. 2013 May;14(6):552-62. doi: 10.1016/S1470-2045(13)70093-7. Epub 2013 Apr 16. Lancet Oncol. 2013. PMID: 23598172 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical